Contact
searchSearch
HMP Global
Login

Myelodysplastic Syndromes

Myelodysplastic Syndromes
Specialty Channel
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology
News
Phase 3 Results Support Regulatory Submission of Oral Azacitidine Plus Cedazuridine in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
10/28/2026
Emily Estrada
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND...
10/28/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Novel NLRP3 Inhibitor Ofirnoflast Demonstrates Clinical Activity in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial...
09/14/2026
Oncology
News
Luspatercept Provides Durable Transfusion Independence in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the...
09/14/2026
Oncology
News
Advanced Age Does Not Compromise Azacitidine Outcomes in Higher-Risk Myelodysplastic Syndromes
07/27/2026
Emily Estrada
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective,...
07/27/2026
Oncology
News
Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk Myelodysplastic Syndromes
07/22/2026
Stephanie Holland
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial...
07/22/2026
Oncology
News
Early Epoetin Alfa Improves Erythroid Response Without Delaying Transfusion Dependence in Lower-Risk Myelodysplastic Syndromes
07/13/2026
Emily Estrada
Results from the phase 3 EPO-PRETAR trial demonstrated that early initiation of epoetin alfa did not delay progression to transfusion dependence in patients with lower-risk myelodysplastic syndromes, although it significantly improved early...
Results from the phase 3 EPO-PRETAR trial demonstrated that early initiation of epoetin alfa did not delay progression to transfusion dependence in patients with lower-risk myelodysplastic syndromes, although it significantly improved early...
Results from the phase 3...
07/13/2026
Oncology
News
Maximum-Dose Luspatercept Produces Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndromes
07/13/2026
Emily Estrada
Results from the phase 3b MAXILUS trial reinforced the efficacy and safety of maximum-dose luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes, producing durable transfusion independence and sustained erythroid...
Results from the phase 3b MAXILUS trial reinforced the efficacy and safety of maximum-dose luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes, producing durable transfusion independence and sustained erythroid...
Results from the phase 3b...
07/13/2026
Oncology

News

News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology
News
Phase 3 Results Support Regulatory Submission of Oral Azacitidine Plus Cedazuridine in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
10/28/2026
Emily Estrada
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND...
10/28/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Novel NLRP3 Inhibitor Ofirnoflast Demonstrates Clinical Activity in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial...
09/14/2026
Oncology
News
Luspatercept Provides Durable Transfusion Independence in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the...
09/14/2026
Oncology
News
Advanced Age Does Not Compromise Azacitidine Outcomes in Higher-Risk Myelodysplastic Syndromes
07/27/2026
Emily Estrada
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective,...
07/27/2026
Oncology
News
Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk Myelodysplastic Syndromes
07/22/2026
Stephanie Holland
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial...
07/22/2026
Oncology
News
Venetoclax-Based Conditioning Regimen Prior to Allo-HSCT for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
06/30/2026
Emily Estrada
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial...
06/30/2026
Oncology
FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

Interactive Features

Quiz
Safety and Preliminary Activity of Eganelisib in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
Safety of Oral Decitabine Cedazuridine vs Intravenous Decitabine for Patients With MDS or CML
06/02/2024
06/02/2024
Oncology
Quiz
Eltrombopag for Low-Risk Myelodysplastic Syndromes and Severe Thrombocytopenia
01/05/2024
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the phase 2 EQOL-MDS trial indicated that patients who received eltrombopag demonstrated a higher platelet response and less frequent significant bleeding compared to patients who received a placebo.
True or False: Results from the...
01/05/2024
Oncology
Quiz
Haploidentical Donors vs Matched Unrelated Donors for High-Risk MDS
06/09/2023
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a retrospective multicenter study on the use of haploidentical donors for treatment of high-risk MDS, results indicated that overall survival and progression-free survival were significantly higher among patients who...
True or False: In a...
06/09/2023
Oncology
Quiz
Quiz: Post-Transplant Eprenetapopt and Azacitidine Maintenance in TP53-Mutant AML and MDS
10/05/2022
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase 2 trial, post-transplant eprenetapopt and azacitidine maintenance demonstrated promising safety and efficacy in TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
True or False: In a recent phase...
10/05/2022
Oncology
Quiz
Nirogacestat in Young Adult Patients With Desmoid Tumors
10/08/2026
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of...
10/08/2026
Oncology
Quiz
Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
Safety and Preliminary Activity of Eganelisib in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
Polycythemia Vera Management Pre-Survey
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology

Recent News

News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology
News
Phase 3 Results Support Regulatory Submission of Oral Azacitidine Plus Cedazuridine in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
10/28/2026
Emily Estrada
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND...
10/28/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Novel NLRP3 Inhibitor Ofirnoflast Demonstrates Clinical Activity in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial demonstrated that ofirnoflast produced clinically meaningful erythroid responses and durable transfusion independence in patients with lower-risk myelodysplastic syndromes who were refractory, intolerant, or...
Results from a phase 2 trial...
09/14/2026
Oncology
News
Luspatercept Provides Durable Transfusion Independence in Patients With Lower-Risk Myelodysplastic Syndromes
09/14/2026
Emily Estrada
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the COMMANDS trial showed that first-line luspatercept provided more durable transfusion independence and hemoglobin improvement compared with epoetin alfa in patients with erythropoiesis-stimulating agent-naive,...
Updated results from the...
09/14/2026
Oncology
News
Advanced Age Does Not Compromise Azacitidine Outcomes in Higher-Risk Myelodysplastic Syndromes
07/27/2026
Emily Estrada
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective, real-world study demonstrated that azacitidine produced comparable efficacy and tolerability in elderly and younger patients with higher-risk myelodysplastic syndromes, supporting its continued use as first-line...
Results from a retrospective,...
07/27/2026
Oncology
News
Magrolimab Plus Azacitidine Fails to Improve Outcomes in Higher-Risk Myelodysplastic Syndromes
07/22/2026
Stephanie Holland
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial demonstrated that magrolimab plus azacitidine did not improve complete remission or overall survival compared with azacitidine alone in treatment-naïve patients with higher-risk myelodysplastic syndromes and was...
The phase 3 ENHANCE trial...
07/22/2026
Oncology
News
Venetoclax-Based Conditioning Regimen Prior to Allo-HSCT for Older Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
06/30/2026
Emily Estrada
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial demonstrated that incorporating venetoclax into a fludarabine and melphalan conditioning regimen before allogeneic hematopoietic stem cell transplantation showed encouraging clinical promise in older patients with...
Results from a phase 2 trial...
06/30/2026
Oncology
FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use